Reaktionsgleichung
[NH:1]1[CH2:4][CH2:3][CH2:2]1.[CH3:5][N:6]([CH3:28])[C:7]1[N:27]=[C:10]2[CH:11]=[CH:12][C:13]([NH:15][C:16]([C:18]3[N:22]([CH3:23])[N:21]=[CH:20][C:19]=3[C:24](O)=[O:25])=[O:17])=[CH:14][N:9]2[N:8]=1>>[CH3:5][N:6]([CH3:28])[C:7]1[N:27]=[C:10]2[CH:11]=[CH:12][C:13]([NH:15][C:16]([C:18]3[N:22]([CH3:23])[N:21]=[CH:20][C:19]=3[C:24]([N:1]3[CH2:4][CH2:3][CH2:2]3)=[O:25])=[O:17])=[CH:14][N:9]2[N:8]=1Komponenten
3
Versuchsvorschrift
Using azetidine and 5-(2-dimethylamino-[1,2,4]triazolo[1,5-a]pyridin-6-ylcarbamoyl)-1-methyl-1H-pyrazole-4-carboxylic acid, the title compound was prepared in the same manner as described for example 2. Brown solid (93 mg, 42%). MS: m/z=369 (M+H+). Ames test negative.
Quellen und Nachweise
- ORD-Eintrag
- ord-aada900734a54cdf8c012d9557a4f5c7
- Quelldatensatz
- uspto-grants-2016_01
- Patentnummer
- US09227970B2
Verknüpfte Notizen
Wird geladen…